Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
US charges two brothers with novel $25 million cryptocurrency heist
By Nate Raymond BOSTON (Reuters) – Two brothers who studied at the Massachusetts Institute of Technology were arrested on Wednesday…
SLB, Travelers Companies And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today…
Explainer-How Boeing could face the criminal prosecution it avoided in 2021
(Reuters) – The U.S. Justice Department said Boeing breached its obligations under a 2021 agreement that kept the planemaker from…